Moderna stock outlook rises as quarterly profit returns

Published on 11/09/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock gets a lift from a return to quarterly profit. Management also points to stronger vaccine demand abroad.

Moderna strengthens its recovery case

Moderna returned to quarterly profit as revenue rose on stronger international COVID-19 vaccine demand.
Management raised its 2026 revenue-growth outlook and expects further pipeline and regulatory milestones.
Investors will next focus on vaccine demand, oncology readouts and execution against the cost-reduction plan.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna returned to quarterly profit on November 6 as stronger international COVID-19 vaccine demand and government-partnership deliveries lifted sales. The company also raised its full-year revenue-growth outlook, giving investors a clearer sign of progress in its recovery plan.

According to Morningstar, Moderna posted net income of 162 million US dollars in the third quarter, compared with a loss of 200 million US dollars a year earlier. Revenue climbed 29 percent to 1.31 billion US dollars, while diluted earnings reached 0.38 US dollars per share.

Outlook and pipeline milestones

Management now expects total 2026 revenue growth of 15 percent to 25 percent, compared with a previous outlook of up to 10 percent. The company attributed the stronger quarter partly to higher international COVID-19 vaccine sales and deliveries under long-term government partnerships.

The upgraded outlook comes alongside recent regulatory and clinical progress. Moderna received US approval for its mRNA-based influenza vaccine mFLUSIVA, while the company and Merck reported positive late-stage results for the investigational cancer therapy intismeran. Management expects further intismeran readouts, pivotal data in propionic acidemia and additional regulatory approvals.

Moderna stock traded at 239.65 euros on Lang & Schwarz at 16:11 CET on Monday, November 9, 2026.